Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05273385
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nanodropper — DEVICE
    Device to apply liquid medication to eyes

Study Details

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

Key Dates

Start date
Oct 10, 2022
Status verified
Mar 2026
Primary completion
Dec 10, 2024
Completion
Dec 10, 2024

Study Design

Enrollment
16 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: Nanodropper
    Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.
  • No Intervention: Standard of Care Dropper
    Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.

Primary Outcome Measure

Intraocular Pressure (IOP) at Baseline [ Time Frame: At Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143-

Find similar trials in San Francisco, CA

By condition
Glaucoma
By specialty
Ophthalmology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies